Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 246

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 246
---
 Stockholder Approval Date, defined above, and (iii) 2,898,551 Series B Warrants issued September 2024 that will expire eighteen months from the Stockholder Approval Date. |
| (2) | Weighted average remaining contractual life calculation excludes 2,898,551 exercisable Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date                                                                                                                                                                                                                                                                                                           |

During the three and nine months ended September
30, 2023, the Company received aggregate cash proceeds of $ upon the exercise of Bridge Warrants with an exercise price
of $, Non-tradeable Warrants with an exercise price of $, and Tradeable Warrants with an exercise price of $.
There were no warrants exercised during the three months ended September 30, 2024. During the nine months ended September 30, 2024, the
Company received aggregate cash proceeds of $ upon the exercise of January 2024 Pre-Funded Warrants with an exercise price
of $.

The following table summarizes the significant
assumptions used in determining the fair value of equity-classified warrants granted during the nine months ended September 30, 2024:

|                         |     | 2024 |       |   |
|:------------------------|:----|:-----|------:|:--|
| Stock price             |     | $    |  3.36 |   |
| Exercise price          |     | $    |  5.08 |   |
| Risk-free interest rate |     |      |  3.91 | % |
| Expected volatility     |     |      | 95.00 | % |
| Expected term (years)   |     |      |  5.00 |   |
| Expected dividend yield |     |      |  0.00 | % |

F-21 (c) Series A Preferred Stock The holders of shares of Series A Preferred Stock have the rights, preferences, powers, restrictions and limitations as set forth below. Voting Rights- The holders of shares of Series A Preferred Stock are not entitled to any voting rights. Dividends- From and after the date of issuance of any share of Series A Preferred Stock, cumulative dividends shall accrue, whether or not declared by the Board and whether or not there are funds legally available for the payment of dividends, on a daily basis in arrears at the rate of 6.0% per annum on the sum of the Liquidation Value (as defined below